Literature DB >> 19741114

Cannabinoid receptor activation in the basolateral amygdala blocks the effects of stress on the conditioning and extinction of inhibitory avoidance.

Eti Ganon-Elazar1, Irit Akirav.   

Abstract

Despite the efficacy of behavior therapy for human anxiety disorders, extinction-like treatments require repeated cue exposures and are vulnerable to reversal by a number of environmental factors, particularly stress. The endocannabinoid system has recently emerged as important in the regulation of extinction learning and in the regulation of the hypothalamic-pituitary-adrenal axis. Here, we aimed to examine the involvement of the cannabinoid CB(1) receptor in the basolateral amygdala (BLA) in inhibitory avoidance (IA) conditioning and extinction and to test whether cannabinoid activation would reverse the effects of stress on these memory processes. The synthetic full agonist of the CB(1)/CB(2) receptor WIN55,212-2 [R-(+)-(2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]pyrol[1,2,3-de]-1,4- benzoxazin-6-yl)(1-naphthalenyl) methanone monomethanesulfonate] (5 microg/0.5 microl) microinjected into the BLA had no effect on IA conditioning or extinction by itself. However, microinjecting WIN55,212-2 into the BLA before exposing the rats to a stressor reversed the enhancing effects of the stressor on IA conditioning and its impairing effects on IA extinction. Importantly, WIN55,212-2 microinjected into the BLA reduced stress-induced elevations in corticosterone levels. Control experiments demonstrated the following: (1) the effects of WIN55,212-2 could not be attributed to sensorimotor deficits, because these parameters seemed unchanged by WIN55,212-2 microinjected into the BLA; and (2) the CB(1) receptor in the BLA is crucially involved in the extinction of IA, because the CB(1) receptor antagonist AM251 [N-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide] (6 ng/0.5 microl) microinjected into the BLA significantly blocked extinction. Together, our findings may support a wide therapeutic application for cannabinoids in the treatment of conditions associated with the inappropriate retention of aversive memories and stress-related disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19741114      PMCID: PMC6665931          DOI: 10.1523/JNEUROSCI.1223-09.2009

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  65 in total

Review 1.  The labile nature of consolidation theory.

Authors:  K Nader; G E Schafe; J E LeDoux
Journal:  Nat Rev Neurosci       Date:  2000-12       Impact factor: 34.870

Review 2.  Retrieval and reconsolidation: toward a neurobiology of remembering.

Authors:  S J Sara
Journal:  Learn Mem       Date:  2000 Mar-Apr       Impact factor: 2.460

3.  Localization of the CB1 type cannabinoid receptor in the rat basolateral amygdala: high concentrations in a subpopulation of cholecystokinin-containing interneurons.

Authors:  A J McDonald; F Mascagni
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

Review 4.  Molecular bases of long-term memories: a question of persistence.

Authors:  Yadin Dudai
Journal:  Curr Opin Neurobiol       Date:  2002-04       Impact factor: 6.627

5.  Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission.

Authors:  I Katona; E A Rancz; L Acsady; C Ledent; K Mackie; N Hajos; T F Freund
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

6.  High versus low reactivity to a novel environment: behavioural, pharmacological and neurochemical assessments.

Authors:  C M Thiel; C P Müller; J P Huston; R K Schwarting
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

7.  Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections.

Authors:  W J Martin; P O Coffin; E Attias; M Balinsky; K Tsou; J M Walker
Journal:  Brain Res       Date:  1999-03-20       Impact factor: 3.252

Review 8.  Cannabinoids, hippocampal function and memory.

Authors:  R E Hampson; S A Deadwyler
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

9.  Evaluation of CB1 receptor knockout mice in the Morris water maze.

Authors:  S A Varvel; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2002-06       Impact factor: 4.030

Review 10.  The endocannabinoid nervous system: unique opportunities for therapeutic intervention.

Authors:  A C Porter; C C Felder
Journal:  Pharmacol Ther       Date:  2001-04       Impact factor: 12.310

View more
  54 in total

Review 1.  Plastic synaptic networks of the amygdala for the acquisition, expression, and extinction of conditioned fear.

Authors:  Hans-Christian Pape; Denis Pare
Journal:  Physiol Rev       Date:  2010-04       Impact factor: 37.312

2.  The effects anandamide signaling in the prelimbic cortex and basolateral amygdala on coping with environmental stimuli in rats.

Authors:  Mano Aliczki; Istvan Barna; Ibolya Till; Maria Baranyi; Beata Sperlagh; Steven R Goldberg; Jozsef Haller
Journal:  Psychopharmacology (Berl)       Date:  2016-01-26       Impact factor: 4.530

Review 3.  Endocannabinoids and the Endocrine System in Health and Disease.

Authors:  Cecilia J Hillard
Journal:  Handb Exp Pharmacol       Date:  2015

4.  Unique inhibitory synapse with particularly rich endocannabinoid signaling machinery on pyramidal neurons in basal amygdaloid nucleus.

Authors:  Takayuki Yoshida; Motokazu Uchigashima; Miwako Yamasaki; Istvan Katona; Maya Yamazaki; Kenji Sakimura; Masanobu Kano; Mitsuhiro Yoshioka; Masahiko Watanabe
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

Review 5.  Amygdala FAAH and anandamide: mediating protection and recovery from stress.

Authors:  Ozge Gunduz-Cinar; Matthew N Hill; Bruce S McEwen; Andrew Holmes
Journal:  Trends Pharmacol Sci       Date:  2013-10-25       Impact factor: 14.819

6.  Prefrontal Cortex Deep Brain Stimulation Improves Fear and Anxiety-Like Behavior and Reduces Basolateral Amygdala Activity in a Preclinical Model of Posttraumatic Stress Disorder.

Authors:  Roman Reznikov; Francis Rodriguez Bambico; Mustansir Diwan; Roger J Raymond; Mina G Nashed; José N Nobrega; Clement Hamani
Journal:  Neuropsychopharmacology       Date:  2017-09-01       Impact factor: 7.853

7.  Cannabinoid CB1 /CB2 receptor agonists attenuate hyperactivity and body weight loss in a rat model of activity-based anorexia.

Authors:  Maria Scherma; Valentina Satta; Roberto Collu; Maria Francesca Boi; Paolo Usai; Walter Fratta; Paola Fadda
Journal:  Br J Pharmacol       Date:  2017-07-11       Impact factor: 8.739

8.  Endogenous cannabinoid release within prefrontal-limbic pathways affects memory consolidation of emotional training.

Authors:  Maria Morena; Benno Roozendaal; Viviana Trezza; Patrizia Ratano; Andrea Peloso; Daniela Hauer; Piray Atsak; Luigia Trabace; Vincenzo Cuomo; James L McGaugh; Gustav Schelling; Patrizia Campolongo
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

9.  Cannabinoids ameliorate impairments induced by chronic stress to synaptic plasticity and short-term memory.

Authors:  Hila Abush; Irit Akirav
Journal:  Neuropsychopharmacology       Date:  2013-02-20       Impact factor: 7.853

10.  Cannabinoids and Glucocorticoids in the Basolateral Amygdala Modulate Hippocampal-Accumbens Plasticity After Stress.

Authors:  Amir Segev; Irit Akirav
Journal:  Neuropsychopharmacology       Date:  2015-08-20       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.